Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 98

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 98
---
, which could
harm our business significantly.

We could be found liable
for monetary damages, including treble damages and attorneys’ fees, if we are found to have willfully infringed a patent of a third
party. A finding of infringement could prevent us from commercializing our product candidates or any future product candidates or force
us to cease some of our business operations, which could materially harm our business.

Although we have reviewed
certain third-party patents and patent filings that we believe may be relevant to our therapeutic candidates or products, we have not
conducted a freedom-to-operate search or analysis for any of our therapeutic candidates or products, and we may not be aware of patents
or pending or future patent applications that, if issued, would block us from commercializing our therapeutic candidates or products.
Thus, we cannot guarantee that our therapeutic candidates or products, or our commercialization thereof, do not and will not infringe
any third party’s intellectual property.

We may not be successful in obtaining or maintaining necessary rights to product components and processes for our manufacturing and development pipeline through acquisitions and in-licenses.

Presently, we have rights
to certain intellectual property, under issued patents that we own, including U.S. Patent No. 11,708,423 and EP Patent No. 3,519,441,
which relate to CER-1236, as well as additional patents which relate to certain other product candidates. U.S. Patent Application Number
16/646,530 was allowed and later issued on July 25, 2023 as U.S. Patent Number 11,708,423. This patent provides coverage over our CER-1236
product candidate and includes claims directed to a CER comprising, at least in part, a Tim-4phosphatidylserine binding domain and a
TLR signaling domain. Because additional product candidates may require the use of proprietary rights held by third parties, the growth
of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights. In addition, while
we have patent rights directed to certain T cell constructs, we may not be able to obtain intellectual property rights to broader T cell
or engineered T cell constructs.

Our product candidates may
also require specific formulations to work effectively and efficiently and these rights may be held by others. Similarly, efficient production
or delivery of our product candidates may also require specific compositions or methods, and the rights to these may be owned by third